title: Adjuvants and vector systems for allergy vaccines.
abstract: Allergen-specific immunotherapy represents a curative treatment of type I allergies. Subcutaneous immunotherapy is conducted with allergens adsorbed on aluminum hydroxide or calcium phosphate particles, whereas sublingual immunotherapy relies on high doses of soluble allergen without any immunopotentiator. There is a potential benefit of adjuvants enhancing regulatory and Th1 CD4+T cell responses during specific immunotherapy. Molecules affecting dendritic cells favor the induction of T regulatory cell and Th1 responses and represent valid candidate adjuvants for allergy vaccines. Furthermore, the interest in viruslike particles and mucoadhesive particulate vector systems, which may better address the allergen(s) to tolerogenic antigen-presenting cells, is documented.
authors.affiliation: Research and Development, Stallergènes, 6 rue Alexis de Tocqueville, 92160 Antony, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moingeon
authors.forename: Vincent
authors.initials: V
authors.lastname: Lombardi
authors.forename: Nathalie
authors.initials: N
authors.lastname: Saint-Lu
authors.forename: Sophie
authors.initials: S
authors.lastname: Tourdot
authors.forename: Véronique
authors.initials: V
authors.lastname: Bodo
authors.forename: Laurent
authors.initials: L
authors.lastname: Mascarell
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000279:Administration, Cutaneous; D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage*; D000818:Animals; D003888:Desensitization, Immunologic; D016503:Drug Delivery Systems; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D014612:Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D014612:Vaccines